The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.

Over-expression of the proto-oncogene Akt/PKB has been demonstrated in some neuroendocrine tumor models. Akt may activate downstream proteins such as mTOR and p70S6K, inducing tumor proliferation. The rapamycin-derivative RAD001, everolimus, interacts with this pathway by antagonizing mTOR, but its effects on neuroendocrine tumors are largely unknown. We explored the mechanism of action of RAD001 on cell proliferation, hormonal secretion and on Akt/mTOR/p70S6K pathway activation, in a human medullary thyroid carcinoma (MTC) cell-line (TT) and in cells derived from human MTCs. Treatment with RAD001 significantly inhibited cell viability in a dose- and time-dependent fashion, and diminished phosphorylation of Akt downstream targets, mTOR and p70S6K, in both TT cell-line and cultured human MTCs. Akt phosphorylation was not affected by RAD001. RAD001 induced cell-cycle arrest in the G(0)/G(1) phase in TT cells, but had no effect on apoptosis. Moreover, RAD001 did not affect calcitonin and carcinoembryonic antigen secretion in TT cells and in human MTCs. RAD001 seems to have potent anti-proliferative effect in human MTC cells, which suggest that clinical trials of this agent are of considerable interest.

Grozinsky-Glasberg S ，Rubinfeld H ，Nordenberg Y ，Gorshtein A ，Praiss M ，Kendler E ，Feinmesser R ，Grossman AB ，Shimon I ... -  《-》

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.

The mode of action of the somatostatin analog octreotide on neuro-endocrine tumour proliferation is largely unknown. Overexpression of the proto-oncogene Akt/PKB (protein kinase B) has been demonstrated in certain neuro-endocrine tumours: Akt activates downstream proteins including mTOR and p70S6K, which play an important role in cell proliferation. RAD001 (everolimus) is a novel agent that is being trialled in the treatment of neuro-endocrine tumours, and is known to interact with mTOR. We explored the mechanism of action of octreotide, RAD001, and their combination on cell proliferation and kinase activation in a neuro-endocrine tumour cell line (rat insulinoma cell line, INS1). Proliferation assays were used to determine the effects of octreotide, RAD001, and their combination on cell proliferation. Western blotting was used to characterize the expression of phosphorylated Akt, phosphorylated TSC2, phosphorylated mTOR, and phosphorylated 70S6K. Treatment with octreotide and RAD001 inhibited proliferation and attenuated phosphorylation of all downstream targets of Akt: TSC2, mTOR, and p70S6K. In this cell model, octreotide and RAD001 appear to act through a similar pathway and inhibit the Akt-mTOR-p70S6 kinase pathway downstream of Akt. There may be some overlapping effects of the two inhibitors on the mTOR pathway, although it is likely that other additional effects may differentiate the two agents.

Grozinsky-Glasberg S ，Franchi G ，Teng M ，Leontiou CA ，Ribeiro de Oliveira A Jr ，Dalino P ，Salahuddin N ，Korbonits M ，Grossman AB ... -  《-》

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

Zatelli MC ，Minoia M ，Martini C ，Tagliati F ，Ambrosio MR ，Schiavon M ，Buratto M ，Calabrese F ，Gentilin E ，Cavallesco G ，Berdondini L ，Rea F ，degli Uberti EC ... -  《-》

The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

Babchia N ，Calipel A ，Mouriaux F ，Faussat AM ，Mascarelli F ... -  《-》

RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.

Wang ZG ，Fukazawa T ，Nishikawa T ，Watanabe N ，Sakurama K ，Motoki T ，Hatakeyama S ，Omori O ，Ohara T ，Tanabe S ，Fujiwara Y ，Takaoka M ，Shirakawa Y ，Yamatsuji T ，Tanaka N ，Naomoto Y ... -  《-》